Moreover, central/effector memory CD8+ T cells were supposed to be functional tumor-reactive T cells for anti-tumor immunotherapies (Klebanoff et al., 2005) and were observed to be higher in the low-risk group (Figures 4G,H). The gene discussed is CD8A; the disease is neoplasm.